secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001437749-24-016112
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Q1 cash $16.8M; Annamycin CRc 62% in 1st/2nd line AML
---------------------------------------------------------------

- R&D expense $4.3M, G&A $2.4M; cash $16.8M expected to fund operations into Q4 2024.
- MB-106 trial: 20 subjects evaluated; 45% CRc all lines (N=20); 62% CRc in 1st/2nd line (N=13).
- USPTO issued patent for liposomal Annamycin composition; EMA granted Orphan Drug Designation for AML.
- End of Phase 2 FDA meeting expected H1 2024; pivotal trial initiation planned H1 2025; NDA submission potential 2027.
- Formed Annamycin Scientific Advisory Board with Dr. Martin Tallman as inaugural member.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/0001437749-24-016112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/mbrx20240509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer